381 related articles for article (PubMed ID: 36844136)
1. Implications of recent neoadjuvant clinical trials on the future practice of radiotherapy in locally advanced rectal cancer.
Kang MK
World J Gastroenterol; 2023 Feb; 29(6):1011-1025. PubMed ID: 36844136
[TBL] [Abstract][Full Text] [Related]
2. A contemporary assessment of total neoadjuvant therapy (TNT) protocols for locally advanced rectal cancer: adoption and expert perspectives at German Cancer Society (DKG)-certified colorectal cancer centers.
Langheinrich M; Paasch C; Mantke R; Weber K; Benz S; Kersting S
J Cancer Res Clin Oncol; 2023 Oct; 149(13):12591-12596. PubMed ID: 37438538
[TBL] [Abstract][Full Text] [Related]
3. The efficacy and safety of short-course radiotherapy followed by sequential chemotherapy and Cadonilimab for locally advanced rectal cancer: a protocol of a phase II study.
Xu T; Feng L; Zhang W; Li H; Ma H; Abulimiti M; Tan Y; Deng F; Huang W; Zou S; Kang W; Jiang L; Wang Y; Hu C; Chen Y; Zhou H; Tang Y; Jin J
BMC Cancer; 2024 Apr; 24(1):501. PubMed ID: 38641773
[TBL] [Abstract][Full Text] [Related]
4. [Analysis on efficacy and safety of total neoadjuvant therapy in patients with locally advanced rectal cancer with high risk factors].
Ouyang GL; Meng WJ; Shu P; Deng XB; Wu B; Jiang D; Zhuang H; Shen YL; Zhou ZG; Wang ZQ; Wang X
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Apr; 22(4):349-356. PubMed ID: 31054549
[No Abstract] [Full Text] [Related]
5. Survival After Induction Chemotherapy and Chemoradiation Versus Chemoradiation and Adjuvant Chemotherapy for Locally Advanced Rectal Cancer.
Kim JK; Marco MR; Roxburgh CSD; Chen CT; Cercek A; Strombom P; Temple LKF; Nash GM; Guillem JG; Paty PB; Yaeger R; Stadler ZK; Gonen M; Segal NH; Reidy DL; Varghese A; Shia J; Vakiani E; Wu AJ; Romesser PB; Crane CH; Gollub MJ; Saltz L; Smith JJ; Weiser MR; Patil S; Garcia-Aguilar J
Oncologist; 2022 May; 27(5):380-388. PubMed ID: 35278070
[TBL] [Abstract][Full Text] [Related]
6. Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management.
Smith JJ; Chow OS; Gollub MJ; Nash GM; Temple LK; Weiser MR; Guillem JG; Paty PB; Avila K; Garcia-Aguilar J;
BMC Cancer; 2015 Oct; 15():767. PubMed ID: 26497495
[TBL] [Abstract][Full Text] [Related]
7. Total Neoadjuvant Therapy (TNT) versus Standard Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer: A Systematic Review and Meta-Analysis.
Liu S; Jiang T; Xiao L; Yang S; Liu Q; Gao Y; Chen G; Xiao W
Oncologist; 2021 Sep; 26(9):e1555-e1566. PubMed ID: 33987952
[TBL] [Abstract][Full Text] [Related]
8. Preoperative sequential short-course radiation therapy and FOLFOX chemotherapy versus long-course chemoradiotherapy for locally advanced rectal cancer: a multicenter, randomized controlled trial (SOLAR trial).
Kang MK; Park SY; Park JS; Kim HJ; Kim JG; Kang BW; Baek JH; Cho SH; Seo AN; Kim DW; Kim J; Baek SJ; Kim JH; Kim JY; Ha GW; Park EJ; Park IJ; Kim CH; Kang H; Choi GS
BMC Cancer; 2023 Nov; 23(1):1059. PubMed ID: 37923987
[TBL] [Abstract][Full Text] [Related]
9. Korean Society of Coloproctology (KSCP) trial of cONsolidation Chemotherapy for Locally advanced mid or low rectal cancer after neoadjUvant concurrent chemoraDiothErapy: a multicenter, randomized controlled trial (KONCLUDE).
Kim CW; Kang BM; Kim IY; Kim JY; Park SJ; Park WC; Bae KB; Bae BN; Baek SK; Baik SH; Son GM; Lee YS; Lee SH
BMC Cancer; 2018 May; 18(1):538. PubMed ID: 29739356
[TBL] [Abstract][Full Text] [Related]
10. Short-course radiation followed by mFOLFOX-6 plus avelumab for locally-advanced rectal adenocarcinoma.
Shamseddine A; Zeidan YH; Kreidieh M; Khalifeh I; Turfa R; Kattan J; Mukherji D; Temraz S; Alqasem K; Amarin R; Al Awabdeh T; Deeba S; Jamali F; Mohamad I; Elkhaldi M; Daoud F; Al Masri M; Dabous A; Hushki A; Jaber O; Khoury C; El Husseini Z; Charafeddine M; Al Darazi M; Geara F
BMC Cancer; 2020 Sep; 20(1):831. PubMed ID: 32873251
[TBL] [Abstract][Full Text] [Related]
11. The Evolving Neoadjuvant Treatment Paradigm for Patients with Locoregional mismatch Repair Proficient Rectal Cancer.
Bhudia J; Glynne-Jones R
Curr Treat Options Oncol; 2022 Apr; 23(4):453-473. PubMed ID: 35312962
[TBL] [Abstract][Full Text] [Related]
12. [Efficacy and safety of total neoadjuvant therapy versus neoadjuvant chemoradiotherapy in the treatment of locally advanced rectal cancer: a meta-analysis].
Zhang YQ; Sun KG; Lu JY; Ma J; Yao N; Qin ZH; Yao YH
Zhonghua Wei Chang Wai Ke Za Zhi; 2022 Jun; 25(6):531-538. PubMed ID: 35754218
[No Abstract] [Full Text] [Related]
13. Non-operative management after chemoradiotherapy plus consolidation or sandwich (induction with bevacizumab and consolidation) chemotherapy in patients with locally advanced rectal cancer: a multicentre, randomised phase II trial (NOMINATE trial).
Akiyoshi T; Shinozaki E; Taguchi S; Chino A; Hiratsuka M; Tominaga T; Nonaka T; Toda S; Matoba S; Matsui S; Okabayashi K; Mukai T; Hiyoshi Y; Yamaguchi T; Nagasaki T; Yamaguchi K; Ueno M; Kuroyanagi H; Fukunaga Y; Ishizuka N; Konishi T;
BMJ Open; 2022 Mar; 12(3):e055140. PubMed ID: 35304396
[TBL] [Abstract][Full Text] [Related]
14. Short-course radiotherapy combined with CAPOX and Toripalimab for the total neoadjuvant therapy of locally advanced rectal cancer: a randomized, prospective, multicentre, double-arm, phase II trial (TORCH).
Wang Y; Shen L; Wan J; Zhang H; Wu R; Wang J; Wang Y; Xu Y; Cai S; Zhang Z; Xia F
BMC Cancer; 2022 Mar; 22(1):274. PubMed ID: 35291966
[TBL] [Abstract][Full Text] [Related]
15. Surgical and short-term oncological safety of total neoadjuvant therapy in high-risk locally advanced rectal cancer.
Ng YY; Seow-En I; Chok AY; Lee TS; Palanisamy P; Tan EK
ANZ J Surg; 2024 Feb; 94(1-2):175-180. PubMed ID: 37849414
[TBL] [Abstract][Full Text] [Related]
16. Selective use of radiation for locally advanced rectal cancer: one size does not fit all.
Roxburgh CS; Weiser MR
Minerva Chir; 2018 Dec; 73(6):592-600. PubMed ID: 29806758
[TBL] [Abstract][Full Text] [Related]
17. Upfront radical surgery with total mesorectal excision followed by adjuvant FOLFOX chemotherapy for locally advanced rectal cancer (TME-FOLFOX): an open-label, multicenter, phase II randomized controlled trial.
Lee JB; Kim HS; Jung I; Shin SJ; Beom SH; Chang JS; Koom WS; Kim TI; Hur H; Min BS; Kim NK; Park S; Jeong SY; Baek JH; Kim SH; Lim JS; Lee KY; Ahn JB
Trials; 2020 Apr; 21(1):320. PubMed ID: 32264919
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant FOLFOXIRI prior to chemoradiotherapy for high-risk ("ugly") locally advanced rectal cancer: study protocol of a single-arm, multicentre, open-label, phase II trial (MEND-IT).
van den Berg K; Schaap DP; Voogt ELK; Buffart TE; Verheul HMW; de Groot JWB; Verhoef C; Melenhorst J; Roodhart JML; de Wilt JHW; van Westreenen HL; Aalbers AGJ; van 't Veer M; Marijnen CAM; Vincent J; Simkens LHJ; Peters NAJB; Berbée M; Werter IM; Snaebjornsson P; Peulen HMU; van Lijnschoten IG; Roef MJ; Nieuwenhuijzen GAP; Bloemen JG; Willems JMWE; Creemers GJM; Nederend J; Rutten HJT; Burger JWA
BMC Cancer; 2022 Sep; 22(1):957. PubMed ID: 36068495
[TBL] [Abstract][Full Text] [Related]
19. [Comparison of short-term efficacy and perioperative safety between neoadjuvant therapy and total neoadjuvant therapy in patients with locally advanced rectal cancer].
Zhai ZW; Zhang KN; Wang C; Han JG; Ma HC; Wei GH; Yang Y; Wang ZJ
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):274-280. PubMed ID: 32192307
[No Abstract] [Full Text] [Related]
20. Is short-course radiotherapy and total neoadjuvant therapy the new standard of care in locally advanced rectal cancer? A sensitivity analysis of the RAPIDO clinical trial.
Jimenez-Fonseca P; Salazar R; Valenti V; Msaouel P; Carmona-Bayonas A
Ann Oncol; 2022 Aug; 33(8):786-793. PubMed ID: 35462008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
